SURE
Research type
Research Study
Full title
A multi-centre, prospective, non-interventional study investigating the effectiveness of once-weekly subcutaneous semaglutide in a real world adult population with type 2 diabetes
IRAS ID
260916
Contact name
Thozukat Sathyapalan
Contact email
Sponsor organisation
Novo Nordisk A/S
Duration of Study in the UK
1 years, 8 months, 23 days
Research summary
This is an observational (non-interventional) study investigating the use of a drug (in this case semaglutide) in routine clinical practice. This means the decision to initiate the treatment is as per normal clinical practice and the treating physician’s discretion, and clearly separated from the decision to include the patient in the study. Only patients already evaluated by physicians to be eligible for treatment with semaglutide can be included in this study.
Semaglutide is a once weekly injection for the treatment of adult patients with uncontrolled type 2 diabetes. Semaglutide has been studied in this population in the SUSTAIN™ clinical trial development program, where it has shown to improve glycaemic control and result in a reduction in weight when compared to placebo and other antidiabetes medications.
This study aims to complement the findings from the SUSTAIN™ program, by looking at how effective semaglutide is in the real word setting when prescribed as per standard of care to adult patients with type 2 diabetes. The physician will be able to determine the intended dose of semaglutide, adjust any other medication as they see necessary and follow up the patient as per their normal practice.
This study is being sponsored by Novo Nordisk A/S and will be conducted in the UK only at approximately 40 different hospital and GP practices. It is planned that 217 participants will be enrolled; individual participation will last approximately 30 weeks.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
19/SW/0048
Date of REC Opinion
14 Mar 2019
REC opinion
Favourable Opinion